Due to its involvement in both innate and adaptive immune compartments, BTK has emerged as a promising therapeutic target in autoimmune disorders associated with maladaptive B-cell and myeloid cell responses such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis (MS). Here, BTK is linked to myeloid sarcoma.